Key Insights

Highlights

Success Rate

83% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

10.0%

2 terminated out of 20 trials

Success Rate

83.3%

-3.2% vs benchmark

Late-Stage Pipeline

5%

1 trials in Phase 3/4

Results Transparency

20%

2 of 10 completed with results

Key Signals

2 with results83% success

Data Visualizations

Phase Distribution

17Total
Not Applicable (3)
P 1 (10)
P 2 (3)
P 3 (1)

Trial Status

Completed10
Active Not Recruiting3
Recruiting3
Terminated2
Not Yet Recruiting1
Unknown1

Trial Success Rate

83.3%

Benchmark: 86.5%

Based on 10 completed trials

Clinical Trials (20)

Showing 20 of 20 trials
NCT03277638Phase 1Active Not RecruitingPrimary

Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)

NCT04116658Phase 1CompletedPrimary

First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma

NCT02974738Phase 1Active Not Recruiting

A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)

NCT06954636Recruiting

Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational Study

NCT04610229Not ApplicableCompleted

Safety of IMRT Treatment With Inhomogeneous Dose in Patients With Relapsed High-grade Gliomas.

NCT06902350Phase 1Recruiting

Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors

NCT03665545Phase 1Completed

Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma

NCT03213002Phase 1Recruiting

Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

NCT03522298Phase 2CompletedPrimary

Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma

NCT06845020Not Yet Recruiting

CSF Proteomic Characterization of Glioblastomas

NCT03181477Not ApplicableActive Not RecruitingPrimary

Study Evaluating the Efficacy of Radiotherapy With SIB-IMRT, Associated With Temozolomide in Glioblastomas

NCT04128774TerminatedPrimary

Function and Composition of Regulatory B Cells in Participants With Glioblastoma

NCT03232424Phase 1CompletedPrimary

NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

NCT03158389Phase 1CompletedPrimary

NCT Neuro Master Match - N²M² (NOA-20)

NCT03618667Phase 2CompletedPrimary

GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification

NCT03714334Phase 1Terminated

DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma

NCT03291977Phase 3CompletedPrimary

Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME)

NCT03744026Phase 1CompletedPrimary

Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9

NCT03025893Phase 2Unknown

A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme

NCT03075514Not ApplicableCompleted

Ketogenic Diets as an Adjuvant Therapy in Glioblastoma

Showing all 20 trials

Research Network

Activity Timeline